Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement
Authors
Keywords
-
Journal
LEUKEMIA & LYMPHOMA
Volume 53, Issue 11, Pages 2218-2227
Publisher
Informa UK Limited
Online
2012-04-05
DOI
10.3109/10428194.2012.681657
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Within Peripheral Blood Mononuclear Cells, Antibody-Dependent Cellular Cytotoxicity of Rituximab-Opsonized Daudi cells Is Promoted by NK Cells and Inhibited by Monocytes due to Shaving
- (2014) P. V. Beum et al. JOURNAL OF IMMUNOLOGY
- Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis
- (2014) P. V. Beum et al. JOURNAL OF IMMUNOLOGY
- Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
- (2011) W. Hu et al. CANCER RESEARCH
- Understanding and Managing Ultra High-Risk Chronic Lymphocytic Leukemia
- (2011) S. Stilgenbauer et al. Hematology-American Society of Hematology Education Program
- CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
- (2010) H. E. Kohrt et al. BLOOD
- Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
- (2010) William G. Wierda et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models
- (2010) William M. Siders et al. LEUKEMIA & LYMPHOMA
- Cancer and the Complement Cascade
- (2010) M. J. Rutkowski et al. MOLECULAR CANCER RESEARCH
- Complement: a key system for immune surveillance and homeostasis
- (2010) Daniel Ricklin et al. NATURE IMMUNOLOGY
- IL-4 induces protection of vascular endothelial cells against killing by complement and melittin through lipid biosynthesis
- (2009) Sylvester M. Black et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX
- (2009) A. W. Pawluczkowycz et al. JOURNAL OF IMMUNOLOGY
- Predictive Value of Blood and Bone Marrow Flow Cytometry in B-Cell Lymphoma Classification: Comparative Analysis of Flow Cytometry and Tissue Biopsy in 252 Patients
- (2009) William G. Morice et al. MAYO CLINIC PROCEEDINGS
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
- (2008) M. Hallek et al. BLOOD
- Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody
- (2008) Wim K. Bleeker et al. BRITISH JOURNAL OF HAEMATOLOGY
- Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies
- (2008) Ronald P Taylor et al. CURRENT OPINION IN IMMUNOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started